Shedding Light on Neural Stimulation
Taking advantage of optoelectronics, we aim to develop personalized neural stimulation systems.
Innovative solutions
Synergia Medical is pioneering optoelectronics for neural stimulation therapies by developing an innovative, powerful and versatile neural stimulation technological platform.
By doing so, Synergia Medical will improve patients’ quality of life and pave the way to new personalized therapies.
Full range of applications
Synergia Medical’s technology could benefit numerous neurological diseases such as chronic pain, Parkinson’s disease, drug-resistant epilepsy, sleep apnoea and depression.
Synergia Medical’s current IP portfolio includes non-metallic encapsulation of neurostimulators, fast-charging wireless system, a custom optical lead, miniaturized photovoltaic cells and an enhanced electrode.
News and Events
- January 18 2023 SYNERGIA MEDICAL INCREASES SERIES B FUNDING TO €12.8 MILLION WITH AN ADDITIONAL €3.8 MILLION
- November 28 2022 SYNERGIA MEDICAL STRENGTHENS ITS MANAGEMENT TEAM WITH THE APPOINTMENT OF DAN SCHERRER AS COO
- November 2 2022 SYNERGIA MEDICAL RECOGNISED BY EIC ACCELERATOR FOR THE EXCELLENT POTENTIAL OF ITS EPILEPSY TREATMENT SOLUTION
SYNERGIA MEDICAL INCREASES SERIES B FUNDING TO €12.8 MILLION WITH AN ADDITIONAL €3.8 MILLION
Synergia Medical today announced the successful completion of an additional €3.8 million of Series B funding bringing the total to €12.8 million. This allows Synergia Medical to prepare for First-In-Human clinical trials planned for 2024.
SYNERGIA MEDICAL STRENGTHENS ITS MANAGEMENT TEAM WITH THE APPOINTMENT OF DAN SCHERRER AS COO
Synergia Medical announced the appointment of Dan Scherrer as Chief Operating Officer. Dan Scherrer brings over 20 years of experience manufacturing, supply chain, quality management and product development in the medical device field.
SYNERGIA MEDICAL RECOGNISED BY EIC ACCELERATOR FOR THE EXCELLENT POTENTIAL OF ITS EPILEPSY TREATMENT SOLUTION
Synergia Medical announced that it has been awarded a €2.5 million grant from the EIC Accelerator program with the potential for an equity investment from the EU in the future Series C fund raising of a further €7.5 million.